scholarly journals Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

2016 ◽  
Vol 17 (12) ◽  
pp. 1661-1671 ◽  
Author(s):  
Joel W Neal ◽  
Suzanne E Dahlberg ◽  
Heather A Wakelee ◽  
Seena C Aisner ◽  
Michaela Bowden ◽  
...  
Keyword(s):  
Small Cell ◽  
Phase 2 ◽  
Wild Type ◽  
Small Cell Lung ◽  
Open Label ◽  
Multicentre Phase ◽  
Phase 2 Trial ◽  
Third Line ◽  
Randomised Controlled ◽  
Third Line Treatment

scholarly journals Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2016 ◽  
Vol 17 (7) ◽  
pp. 984-993 ◽  
Author(s):  
David Planchard ◽  
Benjamin Besse ◽  
Harry J M Groen ◽  
Pierre-Jean Souquet ◽  
Elisabeth Quoix ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Multicentre Phase ◽  
Phase 2 Trial ◽  
Previously Treated

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 21 (6) ◽  
pp. 786-795 ◽  
Author(s):  
Catherine A Shu ◽  
Justin F Gainor ◽  
Mark M Awad ◽  
Codruta Chiuzan ◽  
Claud M Grigg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document